Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.

OBJECTIVES: To evaluate the efficacy and safety of molnupiravir for intra-household post-exposure prophylaxis (PEP) of COVID-19. METHODS: MOVe-AHEAD was a randomized, controlled, double-blind, phase 3 trial comparing molnupiravir (800 mg twice daily for 5 days) with placebo. Eligible participants were adult, unvaccinated, asymptomatic household contacts of patients with laboratory-confirmed COVID-19. The primary efficacy endpoint was the incidence of COVID-19 through day 14 in modified intention-to-treat (MITT) participants (those who received ≥1 dose of study intervention) without detectable SARS-CoV-2 at baseline, termed the MITT-VN population. Superiority of molnupiravir was prespecified as a stratified one-sided p-value of <0.0249 for the treatment difference in this endpoint. RESULTS: The MITT population comprised 763 participants randomized to molnupiravir and 764 to placebo; 83.6% had anti-SARS-CoV-2 antibodies at baseline. In the MITT-VN population, COVID-19 rates through day 14 were 6.5% with molnupiravir and 8.5% with placebo (one-sided p-value: 0.0848). In the molnupiravir arm, 25/35 of confirmed COVID-19 events (71.4%) occurred after completion of treatment (versus 17/49 [34.7%] for placebo). Adverse event rates were low and similar between molnupiravir and placebo. CONCLUSIONS: Molnupiravir was well-tolerated but did not meet the prespecified superiority criterion, possibly influenced in part by the high pre-existing immunity in the trial population.

Enhanced influenza vaccination among healthcare personnel prevents cases despite community burden.

INTRODUCTION: Influenza vaccination for healthcare personnel is not obligatory in Mexico, and compliance relies on promotion and persuasion. The objective of this study was to determine the impact of influenza vaccination compliance on the reduction of influenza and influenza-like illness among healthcare personnel throughout two consecutive influenza seasons. METHODOLOGY: A retrospective study comparing cases of influenza and influenza-like illness among vaccinated and unvaccinated healthcare personnel registered in a Mexican 500-bed University Hospital surveillance and immunization registry during seasons 2015-16 and 2016-17. RESULTS: Total influenza immunization compliance was 21.3% and 42.7%, respectively. Reduction of the number of influenza-like illness (58 in 2015-16 and 15 in 2016-17; P = 0.0001) and confirmed influenza cases (28 in 2015-16 and 13 in 2016-17; P = 0.036) was evident. During 2016-17, influenza activity in the community was higher than 2015-16 (4800 and 1338 cases, respectively). CONCLUSIONS: Increased influenza vaccination compliance among healthcare personnel was associated with reduction of the overall number of influenza and influenza-like illness cases, even in the setting of high activity of the disease in the community through 2016-17 and reported suboptimal vaccine effectiveness during both seasons.

Septic Pulmonary Emboli and Renal Abscess Caused by Staphylococcus aureus in an HIV-Infected Patient.

Staphylococcus aureus is a common cause of bacteremia in the general population and can lead to serious metastatic infection particularly in immunocompromised persons. However, prompt diagnosis and management can result in favorable outcomes. In the following case report, the clinical course of an HIV-infected man is presented; he developed bloodstream infection (BSI) and associated complications: septic pulmonary embolism, right renal abscess, and ipsilateral renal vein thrombosis. Methicillin-resistant Staphylococcus aureus (MRSA) was identified as the cause of sepsis and successfully treated with surgery and antimicrobials. Intravenous vancomycin was the primary therapy, followed by oral linezolid after resolution of bacteremia.